The Cancer Targeting Dye-Carrier
Circumventing drug toxicity and drug resistance is key to effective anticancer therapy. Da Zen’s products and technologies deliver targeted anticancer drugs, such as simvastatin and cisplatin conjugated to a cancer targeting dye-carrier, exclusively to cancer cells, with the drugs confined to the cancer cells for much longer than current therapies (up to three to four weeks) and no evidence of toxicity to normal organs and tissues. DaZen’s research has also shown that its targeted drugs and technologies can overcome therapeutic resistance by cancer cells to a broad spectrum of therapies, including chemotherapy, hormonal therapy, and targeted therapies with tyrosine kinase inhibitors, Gefitnib, Icotinib, and Everolimus.
This successful broad-spectrum re-sensitization to therapeutic agents has prompted Da Zen to search for the molecular mechanisms of re-sensitization. Previous research at Da Zen’s laboratories has demonstrated that these targeted therapies may promote programmed cell death by altering mitochondrial and lysosomal functions. Further exploration of the mechanisms of re-sensitization for various classes of therapeutic cancer agents at Da Zen can help inform the development of new drug targeting technology. The need to test and develop targeted drug systems in rigorous clinical trials is urgent, and moving discoveries from the laboratory to the clinic can significantly improve survival and quality of life for the millions who suffer from cancer.